Cargando…

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Franchini, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145700/ https://www.ncbi.nlm.nih.gov/pubmed/35629282 http://dx.doi.org/10.3390/life12050614

Ejemplares similares

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A: A case report and literature update
por: Franchini, Massimo, et al.
Publicado: (2023)

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses
por: Focosi, Daniele, et al.
Publicado: (2023)

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

Recombination in Coronaviruses, with a Focus on SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
por: Focosi, Daniele, et al.
Publicado: (2023)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 recombinant XN, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Update on rapid diagnostic testing for SARS-CoV-2
por: Dugerdil, Adeline, et al.
Publicado: (2022)

From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses
por: Focosi, Daniele
Publicado: (2023)

COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review
por: Focosi, Daniele, et al.
Publicado: (2021)

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19
por: Sharun, Khan, et al.
Publicado: (2020)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

SARS-CoV-2 Systemic Effects: New Clues
por: Beltrami, Silvia, et al.
Publicado: (2023)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

SARS-CoV-2-induced senescence as a potential therapeutic target
por: Denholm, Mary, et al.
Publicado: (2022)

Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
por: Wandtke, Tomasz, et al.
Publicado: (2022)

Therapeutic antibodies under development for SARS‐CoV‐2
por: Ma, Zetong, et al.
Publicado: (2021)

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
por: Almagro, Juan C., et al.
Publicado: (2022)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

SARS-CoV-2: To be or not to be vaccinated?
por: Beauchet, Olivier
Publicado: (2021)

SARS-CoV-2 docet
por: Sarli, Leopoldo
Publicado: (2021)

Antibodies, B Cell Responses and Immune Responses to SARS-CoV-2 Infections
por: Martinez-Sobrido, Luis, et al.
Publicado: (2023)

New emerging SARS-CoV-2 variants and antiviral agents
por: Vitiello, A., et al.
Publicado: (2023)

Diagnostic Properties of Three SARS-CoV-2 Antibody Tests
por: Basgalupp, Suelen, et al.
Publicado: (2021)

Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7h7ovin2q2h1i4qmbmq5dor847